Loss of heterozygosity at 3p21 is common in various cancers including nasopharyngeal carcinoma (NPC). BLU is one of the candidate tumor suppressor genes (TSGs) in this region. Ectopic expression of BLU results in the inhibition of colony formation of cancer cells, suggesting that BLU is a tumor suppressor. We have identified a functional BLU promoter and found that it can be activated by environmental stresses such as heat shock, and is regulated by E2F. The promoter and first exon are located within a CpG island. BLU is highly expressed in testis and normal upper respiratory tract tissues including nasopharynx. However, in all seven NPC cell lines examined, BLU expression was downregulated and inversely correlated with promoter hypermethylation. Biallelic epigenetic inactivation of BLU was also observed in three cell lines. Hypermethylation was further detected in 19/29 (66%) of primary NPC tumors, but not in normal nasopharyngeal tissues. Treatment of NPC cell lines with 5-aza-2 0 -deoxycytidine activated BLU expression along with promoter demethylation. Although hypermethylation of RASSF1A, another TSG located immediately downstream of BLU, was detected in 20/27 (74%) of NPC tumors, no correlation between the hypermethylation of these two TSGs was observed (P ¼ 0.6334). In addition to methylation, homozygous deletion of BLU was found in 7/29 (24%) of tumors.
Introduction
Nasopharyngeal carcinoma (NPC) is a prevalent tumor in people of southern Chinese ancestry in southern China and Southeast Asia, reaching a peak incidence of 30-50/10 5 /year. It is rare among other populations in the world except for an intermediate incidence in Eskimos and Northern Africans (Vokes et al., 1997) . Various studies on the etiology of NPC have suggested that both environmental and genetic factors contribute to its distinct geographic distribution. Epstein-Barr virus (EBV) is associated with virtually all NPC, regardless of geographic distribution, ethnic origin and the local prevalence of the disease (Raab-Traub, 1992) . Molecular and cytogenetic studies also show that a variety of genetic abnormalities are involved in NPC pathogenesis, including the disruption of certain tumor suppressor genes (TSGs) such as p16
INK4a (Lo et al., 1996) . However, alterations of other well-established TSGs, such as TP53 and RB1, are relatively rare in this disease compared with other malignancies (Effert et al., 1992; Sun et al., 1993) .
Genetic analyses, such as loss of heterozygosity (LOH) and comparative genomic hybridization (CGH), have demonstrated a high incidence of allelic loss in particular chromosomal regions in NPC (Deng et al., 1998; Chen et al., 1999; Hui et al., 1999; Tsang et al., 1999; Lo et al., 2000; Chien et al., 2001; Fang et al., 2001) , notably 3p and 9p (Huang et al., 1991 Hu et al., 1996; Sung et al., 2000) . LOH of 3p was reported in 75% of NPC cases , and the allelic imbalance of 3p was also detected in 96.3% of tumors (Lo et al., 2000) . Microsatellite marker deletion studies have narrowed the location of NPC-related TSGs to the 3p21.3 region (Lo et al., , 2000 Hu et al., 1996; Sung et al., 2000) .
3p21.3 has also been reported to be frequently deleted in other solid tumors such as lung and breast carcinoma (Kok et al., 1997; Lerman and Minna, 2000) . Functional analysis for TSG(s) at 3p21.3 using monochromosome transfer in NPC cell lines further localized the TSG candidate(s) to a region centered around the microsatellite marker D3S1568 (Cheng et al., 1998) . Recently, hypermethylation of a TSG candidate, RAS association family 1 gene (RASSF1A) at 3p21.3, was reported in 75% of NPC cell lines and 66.7% of primary tumors, although with no homozygous deletion detected in cell lines (Lo et al., 2001) , suggesting that RASSF1A might be one of the NPC TSG candidates at this locus.
We have been searching for putative TSG candidates at the 3p21.3 locus that might be disrupted and involved in NPC pathogenesis. Most of the 3p21.3 locus has been sequenced and a series of genes have been assigned (Lerman and Minna, 2000) . Among several genes checked, BLU appeared to be an ideal candidate. It is approximately 120 kb proximal to the microsatellite marker D3S1568. This gene is 4.5 kb in length and encodes an mRNA with alternative splicing in different tissues. The testis form has 11 exons while the lung form has 12 exons, and both isoforms share a common exon 1 and presumably also a common promoter. The protein sequences of these two isoforms are highly homologous (94% homology). BLU is an attractive TSG candidate, because it is highly expressed in normal lung but silent in most lung cancer cell lines, although few mutations have been detected. In small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC) cell lines, its expression is reduced or absent in 70% of cell lines (Lerman and Minna, 2000) . Moreover, it has been reported recently that overexpression of BLU resulted in 40-80% inhibition of colony formation efficiency of cancer cells, strongly suggesting that BLU is a tumor suppressor (Agathanggelou et al., 2002; Zabarovsky et al., 2002) . Here we report our study on the identification and regulation of a functional BLU promoter and the epigenetic and genetic alterations of this gene in NPC cell lines and primary tumors. We found that BLU is an environmental stress-responsive gene and is regulated by E2F. We further detected a high frequency of promoter hypermethylation, along with homozygous deletion of this gene in NPC, supporting the view that this candidate TSG is involved in NPC pathogenesis.
Results

Identification of a CpG-rich BLU promoter
To define the BLU promoter, sequence upstream of the BLU exon 1 was retrieved from the NCBI database (LUCA12, Accession number AC002481.1) and analysed. A putative BLU promoter was identified by computer analysis (http://www.genomatix.de). This promoter is CpG rich, lacking TATA and CAAT boxes, and having a consensus initiator element (GAACTGA) (Smale, 1997) . These features are typical of a TATA-less promoter. The region spanning this putative promoter and exon 1 fulfilled the criteria of a CpG island (Gardiner-Garden and Frommer, 1987) : GC content, 65.6%; observed/expected CpG ratio, 0.76; and a total of 52 CpG sites in a 642-bp region (Figure 1c ). Within this CpG island, three putative E2F-binding sites were identified at þ 34, À81 and À347 bp with two of them containing double CpG sites. Several other potential transcription factor-binding sites, including Sp1 (three sites), heat-shock factor (HSF) (10 sites) and c-Myb (four sites), were also identified using the transcription factor search program TFSEARCH (http:// www.cbcr.jp/research/db/TFSEARCH.html) ( Figure  1a, b) .
To assess whether this sequence could function to drive transcription, different regions of the sequence were cloned and linked to a luciferase reporter construct. Promoter activities of these fragments were assessed by transient transfection in three cell lines (C666-1, CNE-1, 293). The results showed that the largest fragment (À1131 to þ 72) had the highest activity, while the second largest fragment (À748 to þ 72) was less active than the smallest region (À378 to þ 72), implying that a repressive element resides between À748 and À378. These results indicated that the BLU promoter we identified is indeed functional (Figure 1d ).
The BLU promoter is upregulated by E2F
Three putative E2F-binding sites, I (À347/À354), II (À88/À81) and III ( þ 34/ þ 41) were identified in the BLU promoter (up to -5500 upstream) (Figure 1 ). To test whether E2F binds to this promoter and regulates its activity, gel-shift assays were performed to determine whether E2F could form DNA-protein complexes with these sites. Results showed that there was specific E2F binding to these putative-binding sites (Figure 2a) . The binding could be competed off by excess cold probes but not by cold mutant probes, implying that the binding is specific to these sequences. The formation of supershifted bands after adding anti-E2F but not control antibody showed that the binding is E2F-specific, with E2F1 and E2F3 binding more strongly to these sites ( Figure 2a) . Furthermore, cotransfection of the BLU promoter constructs with an E2F1-expressing vector showed that E2F1 activated the expression of the BLU promoter approximately fivefold compared with the control vector plasmid (Figure 2b ). Taken together, these results clearly demonstrated that E2F can bind to and activate the BLU promoter.
BLU is a stress-responsive gene but its response to heat shock is impaired in hypermethylated cell lines
The 10 HSF-binding sites within the CpG island of the BLU promoter suggest that BLU might be a stressresponsive gene, being regulated by heat shock and other environmental stresses. We assessed this 9-kb region including the putative BLU promoter and its first exon was analysed. The sequence from À360 to þ 282 (as labeled by two vertical lines, sequence shown in (a)) was found to be a CpG island. (d) Analysis of the promoter activities of the BLU promoter constructs. Luciferase activities of these fragments relative to the promoter-less control vector are presented. Data are means and standard deviations of three independent assays. All different constructs of the BLU promoter can drive the transcription of the target gene, although the efficiency differs between cell lines. Enh: enhancer possibility by transient transfection. Different BLU promoter constructs were transfected into cells and heat-shock treated, and their relative luciferase activities were measured together with mock controls. As shown in Figure 3 , the luciferase activities of these constructs were increased after heat-shock treatment, indicating that BLU is indeed a stress-responsive gene, and is probably involved in the cellular protection response against various environmental stresses.
Moreover by semiquantitative reverse transcription (RT)-PCR, we found that in tumor cell lines, the endogenous BLU promoter could also be activated by heat shock and 0% serum starvation, however, this response was impaired when the promoter was hypermethylated. The final level of BLU expression after 431C heat-shock treatment in the methylated NPC cell lines (CNE-2, CNE-1 and C666-1) was much lower than that observed in the unmethylated MY-Z (Hodgkin's lym- 
BLU is highly expressed in normal upper respiratory tract tissues (nasopharynx, larynx, trachea) and testis
The expression of BLU was evaluated in normal adult and fetal tissues by semiquantitative RT-PCR targeting both the testis and lung isoforms. BLU was strongly expressed in normal upper respiratory tissues including adult larynx and trachea. It was also expressed at high levels in testis and fetal kidney, stomach and lung; moderately to weakly expressed in adult lung, breast, cervix, ovary, prostate, kidney, peripheral blood mononuclear cells (PBMC) and other fetal tissues, and nearly undetectable in other adult tissues including heart, skeletal muscle, liver, stomach, colon, rectum, placenta, bone marrow and brain ( Figure 4a ). Moreover, BLU was highly expressed in normal nasopharynx (NPx), the anatomic site of NPC occurrence ( Figure 4b ).
BLU is downregulated and hypermethylated in all NPC cell lines
We have shown above that the BLU promoter is regulated by E2F. It is well known that E2F binding is negatively affected by CpG methylation with consequent suppression of E2F-targeted promoters (Campanero et al., 2000) , such as p14ARF. Therefore, we expected that the BLU promoter would also be affected by CpG methylation. We studied this possibility by first analyzing BLU expression in NPC cell lines and normal nasopharyngeal tissues. Among seven NPC cell lines tested, BLU was weakly expressed in C666-1, HK1, HNE-3 and HONE-1, barely detectable in CNE-1 and CNE-2, and completely silent in HNE-1. In contrast, BLU was strongly expressed in the immortalized nasopharyngeal epithelial cell line NP69 (Tsao et al., 2002) , and normal nasopharyngeal tissues (NPx) (Figure 4b ). The downregulation of BLU in C666-1 and CNE-1 was not due to the lack of cell transcription factors since BLU promoter constructs were active when transfected into these cell lines (Figures 1-3 ). Therefore, we investigated whether epigenetic inactivation by promoter methylation plays a role in the downregulation of BLU in these cell lines. Based on the sequence of the BLU CpG island, a set of primers ( Figure 1a , Table 1 ) located within the promoter and exon 1 were designed for methylation-specific PCR (MSP) analysis of its methylation status. Hypermethylation of the BLU promoter was detected in all NPC cell lines, with hypomethylation also detected in C666-1 and weakly in CNE-1, HK1 and HNE-3 ( Figure 4c ). Relatively less methylation was observed in C666-1, which also showed (Figures 4c and 5c ) and 14 normal PBMC samples from healthy individuals (data not shown). These results reveal a good correlation between BLU hypermethylation and downregulation in NPC cell lines, suggesting that hypermethylation of the BLU promoter silences its expression.
BLU is hypermethylated in NPC tumors but not in normal nasopharyngeal tissues
We further investigated whether downregulation and hypermethylation of the BLU gene could be detected in primary NPC tumors. In nine of 14 tumors with available RNA, BLU expression was found to be downregulated when assessed by semiquantitative RT-PCR (Figure 5a ). Since normal reactive cells within primary tumors express background BLU transcripts, the actual percentage of tumors with BLU downregulation could be even higher than this data indicates. Therefore, we used MSP to examine BLU promoter methylation in bisulfite-treated DNA samples of 29 primary NPC tumors, three nude mice-passaged undifferentiated NPC tumors (C15, C17 and C18) and three normal nasopharyngeal tissue samples. Unmethylated BLU alleles were detected in all NPC samples due to the existence of background normal cells (Figure 5b) . Moreover, hypermethylated BLU alleles were detected in C15 and 19/29 (66%) of NPC tumors, but not in any of the normal tissues ( Figure 5c ). As the percentages of background normal cells were different in each tumor sample, the methylation data might not be precisely correlated with the expression level in a case-to-case basis. However, cases with strong promoter methylation (cases 5, 14, 17 and 18) clearly had downregulated BLU expression.
We further studied the detailed methylation profile of the BLU promoter by bisulfite genomic sequencing (BGS). The 663-bp region (À369 to þ 294) spanning the BLU promoter and exon 1, containing 52 CpG sites, was analysed ( Figure 6 ). The BGS results confirmed our MSP analysis. In CNE-2, HNE-1 and HNE-3 with BLU barely expressed and primarily methylated alleles detected by MSP, the BLU promoter was methylated at nearly every CpG site in every allele sequenced, indicating an epigenetic inactivation of both alleles of this gene in these cell lines. In CNE-1, HK1 and C666-1 with both methylated and unmethylated alleles detected by MSP, BGS also identified both types of alleles. In primary NPC tumors with BLU methylation detected by MSP, methylated alleles were consistently detected by BGS. In contrast, no or very few methylated CpG sites were detected in NP69 and normal nasopharyngeal tissues.
Hypermethylation of RASSF1A in NPC tumors
RASSF1A is a recently identified TSG, physically located immediately downstream of BLU, and its hypermethylation has been reported in NPC (Lo et al., 2001) . In order to determine if there is regional methylation effect, we examined the possible correlation between the hypermethylation of these two TSG candidates. By MSP (Murray et al., 2004) , RASSF1A hypermethylation was detected in 20/27 (74%) of tumor samples (Table 2 ), but not in normal nasopharyngeal tissues (data not shown). No apparent correlation was observed between the methylation status of these two genes in tumors (P ¼ 0.6334, Fisher's exact test).
Activation of BLU expression by
To further test whether hypermethylation of the BLU CpG island directly mediates its repression, NPC cell lines with a hypermethylated BLU (C666-1, CNE-1 and CNE-2) were treated with 5-azad C. After treatment for the duration indicated, the BLU expression level was increased 13.4-fold in CNE-2 (in which the BLU gene was virtually all methylated), 8.5-fold in CNE-1 and 4.5-fold in C666-1, along with an increase of percentage (%) of unmethylated BLU alleles by 6.8-fold in CNE-2, 2.5-fold in CNE-1 and 1.6-fold in C666-1, as detected by MSP (Figure 7) . Demethylation of the BLU promoter was confirmed by BGS (CNE-2/Aza in Figure 6 ). After treatment, percentage methylation (% of methylated CpG sites out of total CpG sites) decreased from 94 to 55% in CNE-2, 84 to 43% in CNE-1 and 33 to 18% in C666-1. These results confirmed that CpG methylation plays a direct role in silencing this gene in NPC.
BLU is deleted in some NPC tumors
TSGs can also be inactivated by genetic mutations like deletions. Semiquantitative multiplex DNA PCR for Figure 7 Induction of BLU expression by 5-Azad C treatment in NPC cell lines, along with demethylation of the BLU promoter and an increase in unmethylated BLU alleles. Top two panels represent the RT-PCR analysis for the expression of BLU and GAPDH, respectively. BLU expression was induced after the treatment. Middle two panels represent the MSP analysis for BLU methylation status in these cell lines before and after the treatment. Unmethylated alleles were detected after the treatment. The bottom panel is the plotted densitometry ratio values, as relative BLU expression levels (blank bars) and % methylation (u/u þ m) of the BLU promoter (filled bars) Figure 8 Representative deletion analysis of BLU in NPC tumors and normal DNA samples by multiplex DNA PCR (top panels of a and b). Densitometry measurement (middle panels of a and b) of PCR products for BLU exons 1 and 2 in each sample, relative to GAPDH, was plotted in the histograms in the middle panels. Samples with densitometry ratios (BLU/GAPDH) lower than 20% (as indicated by the horizontal dash lines) of normal control samples were determined to have a homozygous deletion. The BLU methylation status of each tumor sample is shown in the bottom panels of a and b. Human placenta and PBMC DNA samples were used as controls
Discussion
In order to identify genetic and epigenetic alterations in NPC, a prevalent tumor in our locality, we have analysed the 3p21. 3 region, which is frequently deleted in NPC and other solid tumors. Among a few TSG candidates examined, BLU showed both genetic and epigenetic abnormalities. BLU was hypermethylated and downregulated in all NPC cell lines studied and in a high percentage (66%) of primary NPC tumors. Moreover, homozygous deletion of BLU was found in 24% of NPC tumors. In total, 83% (24/29) of the primary NPC tumors had either genetic or epigenetic inactivation of this gene. These results strongly suggest that BLU is an important candidate TSG in NPC.
The BLU protein is highly conserved in vertebrates, with 88, 88 and 55% homology of the human BLU with its mouse, rat and zebrafish orthologs. We also found that the BLU promoter is highly conserved in these species (Tao et al., unpublished) . BLU shares 31% identity with proteins of the MTG/ETO family of transcription factors and suppressin -an inhibitor of cell proliferation (Lerman and Minna, 2000) . However in our bio-informatics analysis, their homology at the zinc-finger-MYND domain can be as high as 45%. BLU is assumed to be a soluble protein. Our analysis also showed that BLU is mainly a cytoplasmic but also nuclear protein. It thus has been suggested that BLU may be involved in cell cycle regulation and may suppress the growth of tumor cells (Lerman and Minna, 2000) . Among the ETO family proteins, MTG8 (ETO, CBFA2T1) is a repressor interacting with the HDAC1 complex (Wang et al., 1998) , while another ETO protein MTG16 (CBFA2T3) is a putative TSG downregulated in breast cancer (Kochetkova et al., 2002) . Both MTG8 and MTG16 are the partner genes of AML1 in chromosomal translocations in acute myeloid leukemia (AML). Suppressin has also been shown to be an inhibitor of cell cycle entry (LeBoeuf et al., 1998) . A recent report showed that overexpression of BLU resulted in 40-80% inhibition of colony formation efficiency of cancer cells, strongly suggesting that BLU is a tumor suppressor (Agathanggelou et al., 2002; Zabarovsky et al., 2002) . Missense mutations of BLU have been reported infrequently in 4/61 lung cancers (Lerman and Minna, 2000) . However, ectopic expression of BLU had no effect on the induction of apoptosis of cancer cells (Ji et al., 2002) , suggesting that its tumor suppressive activity is different from that of apoptosisinducing TSGs.
BLU transcripts were highly expressed in testis and normal tissues of the upper respiratory tract system (larynx, trachea and nasopharynx), but weakly or not expressed in other normal tissues (Figure 4a ). This is in agreement with its tissue-specific expression pattern previously reported (Lerman and Minna, 2000) . In contrast to adult tissues, BLU was expressed at moderate to high levels in all fetal tissues, implying that BLU has specific functions in embryonic development.
In NPC tumors, BLU was inactivated in 83% of cases by either promoter hypermethylation or homozygous deletion. BLU hypermethylation has also been reported in 5-20% of lung, kidney and neuroblastoma tumors (Agathanggelou et al., 2002) . The frequent genetic and epigenetic inactivation of BLU in NPC points to the importance of this gene in the pathogenesis of this disease. Additional functional studies of this gene are currently being carried out in our lab to better define its role in cell control and tumor suppression. The fact that BLU is a stress-responsive gene is consistent with this idea since silencing of BLU will impair the cellular protective response to environmental stresses in the nasopharynx site where carcinogenic pollutants from air often precipitate and accumulate. Therefore, NPC has been suggested as a tumor related to indoor air pollution. A previous study on NPC risks with occupational history together with diet, alcohol consumption and tobacco in Malaysian Chinese also showed that occupational exposure to wood dust is a high-risk factor for NPC . Interestingly, the Drosophila BLU homolog actually interacts with the heat-shock protein 68 (Giot et al., 2003) , whether the human BLU also has the same interaction needs further investigation. Moreover, the polymorphism of a stress protein gene HSP70-2 has been shown recently to be associated with NPC susceptibility in Northern Africans (Jalbout et al., 2003) . Activation of heat stress protein HSP27 has also been reported in Chinese NPC .
3p21.3 is one of the loci for NPC-associated candidate TSGs revealed by LOH and other functional studies (Cheng et al., 1998) . This region is also frequently deleted in other tumors such as lung and breast carcinoma, and has been suggested as the locus for lung tumor suppressors (Kok et al., 1997; Lerman and Minna, 2000; Zabarovsky et al., 2002) . Various genetic studies have been carried out to isolate candidate TSGs at this locus (Lerman and Minna, 2000) . Recently a TSG candidate at this locus, RASSF1A, was reported to be frequently methylated in lung carcinoma (Dammann et al., 2000; Agathanggelou et al., 2001; Burbee et al., 2001) , breast cancer Burbee et al., 2001) , renal cell carcinoma (Dreijerink et al., 2001) , phaeochromocytomas and neuroblastoma tumors (Astuti et al., 2001) , gastric adenocarcinoma , bladder carcinoma , ovarian cancer ) and Hodgkin's lymphoma (Murray et al., 2004) . RASSF1A was also reported to be hypermethylated at high frequency in NPC tumors (Lo et al., 2001) . We detected its hypermethylation in 74% of the NPC tumors examined. However, despite the fact that RASSF1A and BLU are physically located next to each other at 3p21.3, no correlation between the hypermethylation of these two genes was found in primary tumors, ruling out the possibility of a regional methylation effect.
We noticed that, in NPC cell lines, BLU tends to be methylated throughout the entire promoter and exon 1, while in primary tumors it is more frequently methylated in the proximal transcribed exon 1 region in a patchy pattern. This type of methylation spreading from the proximal transcribed region to the core promoter during tumor progression has been observed for several other genes (Singal and vanWert, 2001; Yoshikawa et al., 2001) , and has been suggested to be a characteristic feature of aging and neoplastic transformation (Baylin et al., 1998; Turker, 2002) . For TSGs p16
INK4a and p15
INK4b , methylation starts from the exonic region and then spreads to the promoter (Nosaka et al., 2000; Nguyen et al., 2001) , as observed here for BLU. The methylation of E-cadherin and RASSF1A promoters also increases with tumor progression in breast carcinoma Nass et al., 2000; Yan et al., 2003) .
Both methylated patches in BLU (one at the distal promoter and one at the proximal transcribed exon 1) are near to the E2F-binding sites and we confirmed that E2F1, 3 and 4 bind to these sites. These results not only imply that the BLU gene is an E2F-regulated gene and therefore is cell cycle-regulated, but also suggests a mechanism of methylation initiation from these sites. The binding of E2F will facilitate the recruitment of DNA methyltransferase through its interaction with RB (Robertson et al., 2000) and then initiates and spreads methylation to the entire promoter and exon 1 (Figure 9 ). The presence of CpG methylation over the entire BLU promoter in NPC cell lines established from late-stage tumors (CNE-2, stage III; HNE1 and HONE1, with cervical lymph node metastasis) (Glaser et al., 1989; Zhang et al., 1983 ) and a late-stage metastatic nasal lymphoma (only the two CpG sites at the E2F site II remained unmethylated), but mostly patchy pattern methylation in primary NPC and primary nasal lymphoma (Tao et al., unpublished) , is consistent with this interpretation of methylation progression in BLU with disease stages. The exclusive lack of methylation of the two CpG sites at the E2F site II in the core promoter in a metastatic nasal lymphoma further supports an important role of E2F binding in the initiation and spreading of CpG methylation during disease progression. This methylation spread to the entire promoter in cell lines and metastatic tumors also implies that the epigenetic inactivation of BLU probably occurs at a relatively late stage in the cascade of NPC tumorigenesis.
CpG islands are frequently associated with cellular gene promoters and normally remain unmethylated in normal cells (Baylin et al., 1998) . Aberrant hypermethylation of CpG islands is common in tumors, especially for those islands associated with TSG promoters. The consequence of this hypermethylation is the loss of TSG function, which contributes to tumorigenesis. Hypermethylation of CpG islands of TSG promoters has been widely reported, such as p16
INK4a , p15
INK4b
, VHL, RASSF1A, etc. (reviewed in Baylin et al., 1998) . Our demonstration of BLU hypermethylation adds additional example to this growing list of TSGs inactivated by an epigenetic mechanism in tumors. The discovery of new hypermethylated TSGs provides both new molecular diagnostic tumor markers and therapeutic strategies. Thus, hypermethylation of TSG promoters has been detected not only in primary tumors, but also in serum (Esteller et al., 1999) , sputum (Palmisano et al., 2000) , stool (Dong et al., 2001) , bodily fluids (Goessl et al., 2000) , ductal lavage fluid (Evron et al., 2001 ) and saliva (Rosas et al., 2001 ) of cancer patients. Moreover, clinical trials using the DNA methyltransferase inhibitor 5-azad C or 5-aza-cytidine have been carried out in several research centers on myelodysplastic syndrome patients (Wijermans et al., 2000) and cancer patients (van Groeningen et al., 1986) . These trials were designed to demethylate and reactivate hypermethylated and silenced genes and thus restore normal cell growth control or induce apoptosis in tumor cells. We have shown here that in NPC cell lines the BLU promoter could be demethylated and its expression activated by 5-azad C, suggesting that NPC is also a suitable target for this treatment. Indeed, such trial has been commenced by our groups and has yielded promising results (Chan et al., 2004) .
In summary, we have identified the functional BLU promoter and found that it is stress-responsive and E2F-regulated. We also discovered the inactivation of BLU by both epigenetic and genetic mechanisms in a high percentage of NPC tumors. Thus, BLU fulfills the criteria of being a new-age tumor suppressor (Balmain, 2002) . Further studies of this gene in NPC will be carried out on the function of its encoded protein, its mutations in tumors and the role of this protein in NPC pathogenesis. BLU may even be an attractive target for developing therapeutic strategies towards NPC. Figure 9 Proposed model of methylation spreading in the BLU promoter during tumor progression. The E2F binding can act as a tether to recruit DNA methyltransferase (DNMT) through RB and then histone deacetylase (HDAC) complex (Robertson et al., 2000) . DNMT starts to spread CpG methylation from the exon 1 and the distal promoter to the entire promoter. Meanwhile, the binding of Sp1 may also protect the core promoter and E2F sites from methylation (Macleod et al., 1994) 
Materials and methods
Tumor and normal tissue samples, cell lines NPC tumor biopsy specimens were obtained from the MacKay Memorial Hospital, Taipei, Taiwan (NPC-V), and from the Department of Otolaryngology, National University Hospital, Singapore (NPC-NH). DNA and RNA samples of normal nasopharyngeal tissue have been described previously (Feng et al., 2000; Srivastava et al., 2000) . DNA was also extracted from normal PBMCs purified from healthy donors.
Nude mice-passaged undifferentiated NPC tumors, C15, C17 and C18 are derived from North Africans (Busson et al., 1988) . NPC cell lines C666-1 (EBV positive) (Cheung et al., 1999) , CNE-1, CNE-2, HNE-1, HNE-3 and HONE-1 (all EBV negative) are all derived from undifferentiated Chinese NPC tumors, while HK1 is from a well-differentiated Chinese NPC (Glaser et al., 1989; Lo et al., 2001) . NP69 is an immortalized nasopharyngeal epithelial cell line by SV40 T-antigen and maintains many characteristics of normal nasopharyngeal epithelial cells (Tsao et al., 2002) . Human embryonic kidney (HEK) 293 cell line (ATCC, Manassas, VA, USA) was also used.
5-azad c and heat-shock treatment of cell lines
Cell lines were maintained at 371C in RPMI 1640 or DMEM medium supplemented with 10% fetal bovine serum, 2 mM glutamine, 10 mM HEPES and 100 U/ml of penicillin and streptomycin. For heat-shock treatment of cell lines with methylated (CNE-2, CNE-1 and C666-1) or unmethylated (Hodgkin's lymphoma cell line MY-Z and breast carcinoma cell line MCF-7) BLU promoter, cells were freshly-seeded to 3 Â 10 5 /ml and allowed to grow overnight. T75 flasks containing cells were incubated in a 431C water bath for 40 min, and then recovered at 371C for 2 h.
For heat-shock treatment after transient transfection, transfected cells were incubated at 371C for 24 h, then in a 431C water bath for 40 min, and further recovered at 371C for 24 h.
Cloning of the BLU promoter, plasmid constructs and transfection
Different regions of the BLU promoter were cloned by PCR from normal human placenta DNA (Sigma-Aldrich). Primers are listed in Table 1 . PCR was carried out with a high-fidelity thermal polymerase (Platinum Pfx DNA polymerase, Life Technologies, Gaithersburg, MD, USA) with 10% DMSO. The sequences and orientation of the cloned fragments were confirmed by sequencing. These fragments were linked to the promoter-less plasmid -pGL2-Enhancer Vector (Promega, Madison, WI, USA) to create p(À378)BLUEN, p(À748)BLUEN and p(À1131)BLUEN. Plasmids used for transfection were isolated and purified by EndoFree Plasmid Maxi Kits (Qiagen GmbH, Germany).
The promoter activity of these fragments was tested by transient transfection of 1 mg plasmid DNA in C666-1, 293 and CNE-1 cell lines using LipofectAMINE 2000 (Life technologies). Cell lines were also transiently cotransfected with 1 mg of the constructs and 1 mg of the E2F1-expressing vector -e2f1-pcDNA3 (a gift from Dr Keith Robertson, NCI, NIH, Maryland) or pGL2-basic (Promega, Madison, WI, USA) by using LipofectAMINE 2000 or Transfast (Promega). Promoter activities were assessed by measuring the luciferase levels of cell lysates, according to the protocol from the supplier (Promega). At least three independent assays were conducted. The SV40 promoter plasmid -pGL2-Control Vector (Promega) was used as a control to normalize the different transfection efficiencies among different cell lines in all transfection assays.
Electrophoretic mobility-shift assay (EMSA) Double-strand oligo probes and their mutants containing the wild type or mutant E2F-binding site sequences in the BLU promoter were synthesized by Invitrogen (Carsbad, CA, USA): site I: ggagccgggacGCGAGAAAtagaggaacca; site II: acccgcccggatTTAGGCGCgagccacctc; site III: tcctgtcccagacTTTGGCACcgtcggggt (E2F-binding sites are shown in capital letters, underlined dinucleotides were mutated to AT in mutant probes). These probes were end-labeled with g-32 p-ATP (Amersham Biosciences, Little Chalfont, England). Binding reactions were performed in Gel-Shift Binding Buffer (Promega), with 5 mg of Raji nuclear extract (Geneka Biotechnology, Inc., Carsbad, CA, USA), 0.5 mg of E2F1 protein (Proteinone Inc., College Park, MD, USA) and 25 ng of poly-dI:dC in a total volume of 20 ml. Reaction components were added to the tubes on ice and mixed gently by pipetting. Reactions were incubated for 20 min at 61C with or without cold competitor oligonucleotides or mutant oligonucleotides or antibodies as indicated. Labeled probe was then added and the mixture was incubated for another 20 min. Reaction mixtures were then separated on a 5% acrylamide gel (38 : 2 acrylamide:bisacrylamide) at 41C, 200 V for 2 h. The gel was then dried and autoradiographed. Excess amount (10-, 100-or 200-fold) of cold probes as specific competitors and excess mutant probes as nonspecific competitors were used to determine the binding sequence specificity in competition assays. In all, 4 ml of monoclonal antibodies against E2F1, 2 and 4 (Geneka Biotechnology) were used in the supershift experiment to determine if the binding was E2F-specific, with a monoclonal antibody against Actin (Dako, Glostrup, Denmark, #M0851) as control.
Semiquantitative RT-PCR
Normal tissue RNA samples were purchased from Clontech for trachea, prostate, bone marrow and testis (CLONTECH Laboratories, Inc., Palo Alto, CA, USA) and Stratagene for other adult and fetal tissues (Stratagene, La Jolla, California, USA). RT-PCR primers detecting both the testis and lung isoforms of BLU are listed in Table 1 . The GAPDH was used as a control, and its primers were designed according to the GAPDH mRNA sequence (NCBI nucleotide database Accession number M33197). Total RNA was extracted from cell pellets or tumor tissues by TRI REAGENT (Molecular Research Center, Inc., Cincinnati, OH, USA). RT-PCR was performed as described by using AmpliTaq Gold (Applied Biosystems, Foster City, CA, USA) instead of AmpliTaq (Tao et al., 1998) . The PCR program started with an initial denaturation at 951C for 10 min, followed by 30 cycles (941C for 30 s, 51 or 601C for 30 s and 721C for 30 s) of amplification, with a final extension at 721C for 10 min. PCR bands were visualized under UV light, photographed and semiquantitated with the EagleEye digital gel documentation system and the supplied densitometry software (EagleSight Software, version 3.2, Stratagene). Initial studies on the standardization curves of RT-PCR cycle number versus product yield for BLU and GAPDH showed that linear amplification occurred between 30-50 cycles for BLU and 15-30 cycles for GAPDH control (data not shown) (Tao et al., 2002) . Therefore 30 and 25 cycles of PCR were used for our semiquantitative RT-PCR analysis for BLU and GAPDH respectively.
DNA extraction, bisulfite treatment and BGS
Genomic DNA was extracted from tumors, normal tissues and cell pellets with TRI REAGENT. DNA bisulfite treatment and BGS were performed as previously described (Tao et al., 1998 (Tao et al., , 1999 .
Methylation-specific PCR
MSP was conducted according to our previous report (Tao et al., 1999) . MSP primers are listed in Table 1 . All MSP primers have been tested for not amplifying any unbisulfited DNA. MSP for RASSF1A was performed as described (Murray et al., 2004) .
Deletion analysis of BLU by multiplex PCR
Deletion of the BLU coding exon 1 or 2 was examined using multiplex DNA PCR. A 363-bp fragment of the BLU gene and a 245-bp fragment of the GAPDH gene as internal control were coamplified. The PCR was performed in a 12.5 ml reaction mixture consisting of 0.4 mM of primer BLUA (located at the coding exon 1 of BLU) and BLUC (located at exon 2), 0.2 mM of GAPDH primers (Table 1) , 0.2 mM of dNTP, 1.5 mM of MgCl 2 , 1 Â PCR Buffer II, 0.47 U of AmpliTaq Gold and 100 ng of template DNA. PCR was conducted as 951C for 10 min, then 40 cycles (941C, 30 s; 521C, 30 s; 721C, 30 s), followed by 721C for 10 min. PCR products were analysed on 1.8% agarose gels. In order to minimize the amplification of GAPDH pseudogene, primer GAPDHIN was designed to hybridize within the intron, according to GAPDH mRNA and gene sequences (Accession number J04038).
PCR bands were then photographed and analysed with the EagleEye digital gel documentation system and the supplied densitometry software. The average signal ratios (BLU/ GAPDH) for normal PBMC and placenta DNA samples were 0.5270.1 (mean7s.d.). Samples with a signal ratio less than 20% (o0.104) of the normal control samples were determined to have a homozygous deletion (Kourea et al., 1999) . However, this method is not suitable for assessing heterozygous deletion.
